by Richard Daverman, PhD
June 8, 2012 -- Chongqing Zhifei Biological Products and Merck signed an MOU that expands the existing partnership between the two companies by entrusting Zhifei with the responsibility for China marketing of Merck’s RotaTeq, an oral pentavalent live rotavirus vaccine. Merck, known as MSD outside the US and Canada, already sells the vaccine in 85 countries. Last year, Zhifei took over the China marketing of Merck’s MMR/rubella and Penumovax 23 vaccines. More details....
Stock Symbols: (SHE: 300122) (NYSE: MRK)
